Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-Long-Acting Basal Insulin

Pharmaceutical Research - United States
doi 10.1007/s11095-012-0739-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Insulin Toujeo® — A Novel Basal Long-Acting Insulin Formulation. Part 2. Clinical Efficacy and Safety

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY
2016English

Insulin Degludec Aspart: The First Co-Formulation of Insulin Analogues

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2014English

An Indirect Treatment Comparison of the Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine/Lixisenatide (iGlarLixi) in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin

Journal of Medical Economics
Health Policy
2017English

The Use of Ultra-Long-Acting Insulin Analogue Degludec in Type 1 Diabetes Mellitus in Clinical Practice: The Influence on Quality of Life and Satisfaction With Treatment

Almanac of Clinical Medicine
2016English

Systematic Review and Economic Evaluation of a Long-Acting Insulin Analogue, Insulin Glargine

Health Technology Assessment
MedicineHealth Policy
2004English

Long Acting Insulin Glargine Overdose, a Surprising Long Lifetime

Toxicology Communications
2019English

Budget Impact of Long-Acting Insulin Analogues: The Case in Brazil

PLoS ONE
Multidisciplinary
2016English

Long-Acting Insulin: Slow Release of Insulin From a Biodegradable Matrix Implanted in Diabetic Rats

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
1983English

Proinsulin-Transferrin Fusion Protein as a Novel Long-Acting Insulin Analog for the Inhibition of Hepatic Glucose Production

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy